Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml
Download PDF
Synlett 2018; 29(11): 1437-1440
DOI: 10.1055/s-0037-1609684
DOI: 10.1055/s-0037-1609684
letter
Catalyst-Free One-Pot Synthesis of Chromeno-Imidazo-Pyridinones by an Aza-Michael Addition/Rearrangement/Heterocyclization Tandem Reaction
Authors
Thanks are due to University of Aveiro and FCT/MEC for the financial support of the QOPNA research project (FCT UID/QUI/00062/2013); to the CICECO-Aveiro Institute of Materials (POCI-01-0145-FEDER-007679; FCT UID/CTM/50011/2013), financed by national funds and, when appropriate, co-financed by FEDER under the PT2020 Partnership Agreement; and to the Portuguese NMR Network. We would like also to thank FCT/MEC and the General Directorate for Scientific Research and Technological Development–DGRSDT of Algeria and Agence Thématique de Recherche en Sciences et Technologie ATRST for approving the co-financed bilateral project PT-DZ/0005. We further wish to thank CICECO for funding the purchase of the single-crystal X-ray diffractometer.
Further Information
Publication History
Received: 13 January 2018
Accepted after revision: 20 March 2018
Publication Date:
07 May 2018 (online)
Abstract
A one-pot synthesis of a novel series of chromeno-imidazo-pyridinone derivatives from 3-[(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl]chromones and ethane-1,2-diamine at room temperature under catalyst-free conditions has been successfully developed. This approach involves a tandem aza-Michael addition reaction, a chromone-to-chromanone rearrangement, and a heterocyclization sequence, leading to chromeno-imidazo-pyridinone polyheterocycles. The structure and absolute configurations of the new compounds were elucidated by a combination of 1D- and 2D-NMR analyses and single-crystal X-ray diffraction.
Key words
chromones - ethanediamine - chromeno-imidazo-pyridinones - one-pot synthesis - tandem reaction - aza-Michael additionSupporting Information
- Supporting information for this article is available online at https://doi.org/10.1055/s-0037-1609684.
- Supporting Information (PDF)
- CIF File (ZIP)
-
References and Notes
- 1 Soural M. Bouillon I. Krchňák V. J. Comb. Chem. 2008; 10: 923
- 2a Mavel S. Renou JL. Galtier C. Snoeck R. Andrei G. Balzarini J. De Clercq E. Gueiffier A. Arzneim. Forsch. 2001; 51: 304
- 2b Hanson SM. Morlock EV. Satyshur KA. Czajkowski C. J. Med. Chem. 2008; 51: 7243
- 3a Tomczuk BE. Taylor CR. Jr. Moses LM. Sutherland DB. Lo YS. Johnson DN. Kinnier WB. Kilpatrick BF. J. Med. Chem. 1991; 34: 2993
- 3b Pettit GR. Collins JC. Knight JC. Herald DL. Nieman RA. Williams MD. Pettit RK. J. Nat. Prod. 2003; 66: 544
- 3c Kim D. Wang L. Hale JJ. Lynch CL. Budhu RJ. MacCoss M. Mills SG. Malkowitz L. Gould SL. DeMartino JA. Springer MS. Hazuda D. Miller M. Kessler J. Hrin RC. Carver G. Carella A. Henry K. Emini EA. Bioorg. Med. Chem. Lett. 2005; 15: 2129
- 3d Pimentel M. Park S. Mirocha J. Kane SV. Kong Y. Ann. Intern. Med. 2006; 145: 557
- 3e Scarpignato C. Pelosini I. Digestion 2006; 73: 13
- 3f Markey MD. Kelly TR. J. Org. Chem. 2008; 73: 7441
- 3g Boggs S. Elitzin VI. Gudmundsson K. Martin MT. Sharp MJ. Org. Process Res. Dev. 2009; 13: 781
- 3h Heidari A. J. Data Min. Genomics Proteomics 2016; 7: e125
- 4a Rahmati A. Khalesi Z. Int. J. Org. Chem. 2011; 1: 15
- 4b Volpi G. Magnano G. Benesperi I. Saccone D. Priola E. Gianotti V. Milanesio M. Conterosito E. Barolo C. Viscardi G. Dyes Pigm. 2017; 137: 152
- 5a Enguehard C. Allouchi H. Gueiffier A. Buchwald SL. J. Org. Chem. 2003; 68: 4367
- 5b Aginagalde M. Vara Y. Arrieta A. Zangi R. Cebolla VL. Delgado-Camón A. Cossío FP. J. Org. Chem. 2009; 75: 2776
- 5c Nair DK. Mobin SM. Namboothiri IN. Org. Lett. 2012; 14: 4580
- 5d Adib M. Sheikhi E. Rezaei N. Tetrahedron Lett. 2011; 52: 3191
- 5e Stasyuk AJ. Banasiewicz M. Cyrański MK. Gryko DT. J. Org. Chem. 2012; 77: 5552
- 5f Chandra MD. Reddy DR. Nageswara RS. Adimurthy S. Adv. Synth. Catal. 2013; 355: 2217
- 5g Talbot E. Richardson M. McKenna JM. Toste FD. Adv. Synth. Catal. 2014; 356: 687
- 6a Talhi O. Silva AM. Curr. Org. Chem. 2012; 16: 859
- 6b Talhi O. Silva A. Curr. Org. Chem. 2013; 17: 1067
- 6c Keri RS. Budagumpi S. Pai RK. Balakrishna RG. Eur. J. Med. Chem. 2014; 78: 340
- 6d Hassaine R. Talhi O. Taibi N. Paz FA. A. Bensaid O. Bachari K. Silva AM. Synlett 2016; 27: 465
- 6e Talhi O. Brodziak-Jarosz L. Panning J. Orlikova B. Zwergel C. Tzanova T. Philippot S. Pinto DC. G. A. Paz FA. A. Gerhäuser C. Dick TP. Jacob C. Diederich M. Bagrel D. Kirsch G. Silva AM. S. Eur. J. Org. Chem. 2016; 2016: 965
- 7 Chromeno-imidazo-pyridinones 2a–e; General Procedure H2N(CH2)2NH2 (10 mmol) was added to a stirred solution of the appropriate chromone 1a–e (1 mmol) in THF (20 mL), and the mixture was stirred for 24 h at r.t. The solvent was then removed under vacuum, and acetone (20 mL) was added to precipitate the solid product, which was collected by filtration and washed with acetone (×2) to afford the yellowish solid product. Good-quality single-crystals suitable for X-ray analysis were obtained only for compound 2a.
- 8 12a-(2-Hydroxyphenyl)-1,2,3,11a,12,12a-hexahydro-6H-chromeno[2,3-d]imidazo[1,2-a]pyridin-6-one (2a) C20H18N2O3. Colorless crystals; yield: 0.28 g (84%); mp 237–239 °C. 1H NMR (300.13 MHz, DMSO-d6): δ = 2.15–2.34 (m, 1 H, H-2), 2.64–2.83 (m, 2 H, H-2, H12), 3.49–3.73 (m, 3 H, H-12, 2 × H-3), 4.52 (br s, 1 H, 1-NH), 4.66 (dd, J 10.8, 5.4 Hz, 1 H, H-11a), 6.69–6.83 (m, 3 H, H-3′, H-5′, H-6′), 6.88 (d, J 8.4 Hz, 1 H, H-10), 6.96–7.07 (m, 1 H, H-8), 7.11–7.22 (m, 1 H, H-4′), 7.33–7.44 (m, 1 H, H-9), 7.69–7.78 (m, 1 H, H-7), 8.06 (s, 1 H, H-5), 11.17 (br s, 1 H, 2′-OH). 13C NMR (75.47 MHz, DMSO-d6): δ = 36.0 (C-2), 42.6 (C-12), 48.3 (C-3), 71.3 (C-11a), 79.6 (C-12a), 102.1 (C-5a), 117.0 and 117.1 (C-3′ and C-10), 118.8 (C-5′), 121.5 (C-8), 123.7 (C-6a), 124.6 (C-1′), 126.1 (C-7), 126.7 (C-6′), 129.9 (C-4′), 133.6 (C-9), 142.0 (C-5), 154.5 (C-2′), 159.2 (C-10a), 176.0 (C-6). HRMS-ESI+: m/z [M + H]+ calcd for C20H19N2O3: 335.1396; found: 335.1380.
- 9 12a-(2-Hydroxyphenyl)-8-methyl-1,2,3,11a,12,12a-hexahydro-6H-chromeno[2,3-d]imidazo[1,2-a]pyridin-6-one (2b) C21H20N2O3. Yellowish solid; yield: 0.27 g (77%); mp 255–256 °C. 1H NMR (300.13 MHz, DMSO-d6): δ = 2.25 (s, 3 H, 8-CH 3), 2.14–2.32 (m, 1 H, H-2), 2.63–2.85 (m, 2 H, H-2, H12), 3.36–3.40 (m, 1 H, H-12), 3.53–3.73 (m, 2 H, H-3), 4.55 (br s, 1 H, 1-NH), 4.61 (dd, J 10.8, 5.1 Hz, 1 H, H-11a), 6.69–6.82 (m, 4 H, H-3′, H-5′, H-6′, H-10), 7.12–7.23 (m, 2 H, H-4′, H-9), 7.53 (d, J 2.1 Hz, 1 H, H-7), 8.04 (s, 1 H, H-5), 11.59 (br s, 1 H, 2′-OH). 13C NMR (75.47 MHz, DMSO-d6): δ = 20.2 (8-CH3), 36.1 (C-2), 42.7 (C-12), 48.4 (C-3), 71.3 (C-11a), 79.6 (C-12a), 102.4 (C-5a), 116.9 and 117.1 (C-3′ and C-10), 118.9 (C-5′), 123.4 (C-6a), 124.7 (C-1′), 126.1 (C-7), 126.8 (C-6′), 129.9 (C-4′), 130.5 (C-8), 134.3 (C-9), 141.9 (C-5), 154.5 (C-2′), 157.3 (C-10a), 176.3 (C-6). HRMS-ESI+: m/z [M + H]+ calcd for C21H21N2O3: 349.1552; found: 349.1577.
- 10 Crystal data for compound 2a: C20H18N2O3, M = 334.36, triclinic, space group P-1, Z = 2, a = 6.8074(7) Å, b = 10.1451(12) Å, c = 11.6511(12) Å, α = 86.729(4)º, β = 79.432(4)°, γ = 89.888(4)°, V = 789.68(15) Å3, μ(Mo-Kα) = 0.096 mm–1, D c = 1.406 mg/cm3, colorless needle, crystal size = 0.22 × 0.08 × 0.08 mm3. Of a total of 13735 reflections collected, 4159 were independent (R int = 0.0590). Final R1 = 0.0589 [I > 2σ(I)] and wR2 = 0.1666 (all data). Data completeness to θ = 25.24°, 99.2%.
- 11 CCDC 1813216 contains the supplementary crystallographic data for compound 2a. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/getstructures.